Silverback Therapeutics (SBTX) Competitors $18.35 +0.48 (+2.69%) As of 07/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock SBTX vs. GMTX, CALT, ZYME, MENS, MBX, AVTE, NLTX, CYBN, BIOA, and VIRIShould you be buying Silverback Therapeutics stock or one of its competitors? The main competitors of Silverback Therapeutics include Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Jyong Biotech (MENS), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), and Virios Therapeutics (VIRI). Silverback Therapeutics vs. Its Competitors Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks Jyong Biotech MBX Biosciences Aerovate Therapeutics Neoleukin Therapeutics Cybin BioAge Labs Virios Therapeutics Silverback Therapeutics (NASDAQ:SBTX) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk. Is SBTX or GMTX more profitable? Silverback Therapeutics' return on equity of -29.62% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Silverback TherapeuticsN/A -29.62% -28.20% Gemini Therapeutics N/A -38.78%-35.88% Which has stronger earnings & valuation, SBTX or GMTX? Gemini Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilverback TherapeuticsN/AN/A-$89.48M-$2.42-7.58Gemini TherapeuticsN/AN/A-$71.87M-$1.00-57.79 Do insiders & institutionals have more ownership in SBTX or GMTX? 74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, SBTX or GMTX? Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500. Does the media refer more to SBTX or GMTX? In the previous week, Silverback Therapeutics and Silverback Therapeutics both had 1 articles in the media. Silverback Therapeutics' average media sentiment score of 0.75 beat Gemini Therapeutics' score of 0.00 indicating that Silverback Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silverback Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gemini Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummarySilverback Therapeutics beats Gemini Therapeutics on 6 of the 9 factors compared between the two stocks. Get Silverback Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBTX vs. The Competition Export to ExcelMetricSilverback TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$661.66M$816.26M$5.54B$9.41BDividend YieldN/A4.84%3.75%4.03%P/E Ratio-7.581.4128.0119.82Price / SalesN/A27.13432.7298.44Price / CashN/A19.5636.1658.27Price / Book2.486.878.125.65Net Income-$89.48M-$4.17M$3.25B$257.91M7 Day Performance2.06%0.03%0.97%2.09%1 Month Performance23.82%2.12%7.36%11.13%1 Year Performance75.68%2.14%31.31%18.40% Silverback Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBTXSilverback TherapeuticsN/A$18.35+2.7%N/A+57.7%$661.66MN/A-7.5883News CoverageHigh Trading VolumeGMTXGemini TherapeuticsN/A$57.74+1.5%N/A+19.7%$2.50BN/A-57.7430CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks3.1252 of 5 stars$12.95-3.0%$21.00+62.2%+43.1%$903.30M$93.38M-8.64460News CoverageMENSJyong BiotechN/A$10.98-5.4%N/AN/A$834.81MN/A0.0031Positive NewsGap UpMBXMBX Biosciences2.3376 of 5 stars$13.28-4.3%$37.50+182.4%N/A$444.37MN/A0.0036Analyst ForecastAVTEAerovate TherapeuticsN/A$9.00-8.4%N/A-86.7%$260.87MN/A-3.0120High Trading VolumeNLTXNeoleukin TherapeuticsN/A$22.26+3.9%N/A-49.2%$209.20MN/A-7.1690High Trading VolumeCYBNCybin2.8641 of 5 stars$7.45-0.3%$85.00+1,040.9%N/A$171.55MN/A-1.7050News CoverageBIOABioAge LabsN/A$4.48-3.2%N/AN/A$160.61MN/A0.00N/AVIRIVirios Therapeutics0.1108 of 5 stars$5.08+6.7%$5.00-1.6%+1,446.4%$97.83MN/A-18.815News CoverageGap Up Related Companies and Tools Related Companies GMTX Alternatives CALT Alternatives ZYME Alternatives MENS Alternatives MBX Alternatives AVTE Alternatives NLTX Alternatives CYBN Alternatives BIOA Alternatives VIRI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SBTX) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silverback Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Silverback Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.